Skip to content
HowShorted

Verve Therapeutics, Inc. short interest in 2023

In 2023, Verve Therapeutics, Inc.'s disclosed short interest ran from 20.77% of shares outstanding on 13 Jan 2023 to 18.40% on 29 Dec 2023, a change of -2.37 percentage points. The year's high was 22.56% on 30 Nov 2023 and its low 17.28% on 31 Jul 2023, averaging 19.95% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.30 days on 31 Jan 2023. Full history: Verve Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Verve Therapeutics, Inc. in 2023

2023 in figures

Start of year
20.77% (13 Jan 2023)
End of year
18.40% (29 Dec 2023)
Change
-2.37 pp
High
22.56% (30 Nov 2023)
Low
17.28% (31 Jul 2023)
Average
19.95%
Highest days to cover
25.30 (31 Jan 2023)
SEC filings marked
8

Every report in 2023

Verve Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202320.77%19.46
31 Jan 202320.81%25.30
15 Feb 202322.03%23.01
28 Feb 202322.16%19.62
15 Mar 202322.15%14.3910-K filed, results (8-K)
31 Mar 202321.83%16.97
14 Apr 202321.72%13.44
28 Apr 202321.22%23.27
15 May 202320.38%21.3310-Q filed, results (8-K)
31 May 202320.00%21.50
15 Jun 202318.67%17.89
30 Jun 202319.16%14.39
14 Jul 202319.24%21.41
31 Jul 202317.28%22.50
15 Aug 202317.53%17.3510-Q filed, results (8-K)
31 Aug 202318.71%19.22
15 Sep 202318.74%16.67
29 Sep 202319.12%14.99
13 Oct 202317.91%15.50
31 Oct 202319.90%9.32
15 Nov 202320.94%3.8910-Q filed, results (8-K)
30 Nov 202322.56%8.32
15 Dec 202317.63%7.43
29 Dec 202318.40%10.99

See also: Verve Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.